NEW YORK STOCK EXCHANGE, INC. · RCUS
+1.08% · +$0.2800 · Vol Not reported
Pre-market · updated 04:01:03 ET
Arcus Biosciences Inc

Arcus Biosciences Inc

Biotechnology
$26.11
Card
Relationship Map

Follow $RCUS

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $RCUS by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
RCUS
Arcus Biosciences Inc
Wed Sep 30 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

47/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Wed Sep 30 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is RCUS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading RCUS catalysts
About Arcus Biosciences Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2018
Employees
601
Country
US

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$25.83
Last session
Day high
$25.83
Last session
Day low
$25.83
Last session
Previous close
$25.83
52W high
$31.57
-17.29% from high
52W low
$13.35
70% of range
Market cap
$3.3B
EPS
$-3.9044
Beta
1.33
Shares out
127.3M
Avg volume
1.6M
VWAP
$25.83
Last session
Price history computed in-house
1W
+4.19%
1M
-12.12%
3M
-13.91%
1Y
+93.69%
YTD
+9.57%
SMA 50 $27.99 · below
SMA 200 $24.74 · above
52W position 70%

RCUS overview

Veridion Score
47
Registered · 2026-09-30
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around RCUS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading RCUS Form 4 filings
Public disclosures

Congress activity in RCUS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for RCUS in the cached public ledger.

Federal contracts

RCUS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RCUS in this window.
Lobbying spend

RCUS lobbying filings, year to date.

Registered lobbying filings matched to Arcus Biosciences Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RCUS in this window.
Loading news for RCUS
Analyst ratings
Sovereign unlock shows live analyst consensus for RCUS.
Options
Sovereign unlock shows live options positioning for RCUS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.